I also compare Clinuvel to other asx biotech stocks. They are profitable due to a failed strategy of inadequately reinvesting in their pipeline, possibly due to the board falling asleep during a dr wright presentation. However, Clinuvel are hopeless and embarrassing with respect to their communication, treatment of shareholders and ability to execute. Wolgen is extremely well paid ( tax free in Monaco) and speaks in riddles and unable to answer a direct question but allegedly delivers market sensitive information selectively during private discussions.
good luck with your investment
I also compare Clinuvel to other asx biotech stocks. They are...
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.79 |
Change
0.290(2.15%) |
Mkt cap ! $690.5M | |||
| Open | High | Low | Value | Volume |
| $13.50 | $13.98 | $13.40 | $1.675M | 122.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250 | $13.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.89 | 57 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |